{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:54:11Z","timestamp":1780624451830,"version":"3.54.1"},"reference-count":56,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Contact Dermatitis"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Real\u2010world data on the effectiveness of upadacitinib on atopic dermatitis (AD), hand eczema (HE) and HE in the context of AD are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the effectiveness and safety of upadacitinib on AD and on HE in patients with AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective observational cohort study includes clinical outcomes: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Hand Eczema Severity Index (HECSI), Photographic guide; and PROMs: average pruritus and pain Numeric Rating Scale (NRS) score of the past week, Patient\u2010Oriented Eczema Measure (POEM), Patient\u2010Oriented Eczema, Dermatology Life Quality Index (DLQI), Atopic Dermatitis Control Tool (ADCT), Patient Global Assessment of Disease (PGAD), Quality Of Life Hand Eczema Questionnaire (QOLHEQ) at baseline, Week 4, and Week 16 of upadacitinib\u2010treated patients. Adverse events were monitored during each visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010eight patients were included, of which 32 patients had HE. At Week 16, EASI\u201075 was achieved by 50.0%. Absolute cutoff score NRS\u2010pruritus \u22644 was reached by 62.5%, POEM \u22647 by 37.5%, DLQI \u22645 by 59.4%, ADCT &lt;7 by 68.8%, and PGAD rating of at least \u2018good\u2019 by 53.1%. HECSI\u201075 was achieved by 59.3% and (almost) clear on the Photographic guide by 74.1%. The minimally important change in QOLHEQ was achieved by 57.9%. Sub\u2010analysis in patients with concomitant irritant contact dermatitis showed no differences. Safety analysis showed no new findings compared to clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Upadacitinib can be an effective treatment for patients with AD and concomitant HE in daily practice. Future studies should focus on the effectiveness of upadacitinib on chronic HE, especially on the different etiological subtypes of HE, including HE in non\u2010atopic individuals.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cod.14276","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T15:49:50Z","timestamp":1673279390000},"page":"351-362","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the <scp>BioDay<\/scp> registry"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4265-9634","authenticated-orcid":false,"given":"Esm\u00e9","family":"Kamphuis","sequence":"first","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2731-9284","authenticated-orcid":false,"given":"Laura","family":"Loman","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1030-2374","authenticated-orcid":false,"given":"Henry L.","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4408-8596","authenticated-orcid":false,"given":"Geertruida L. E.","family":"Romeijn","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6475-6876","authenticated-orcid":false,"given":"Klaziena","family":"Politiek","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical Center Leeuwarden  Leeuwarden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0766-4382","authenticated-orcid":false,"given":"Marie L. A.","family":"Schuttelaar","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13401"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13804"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.432"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2006.06005"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16147"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13308"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14035"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09099.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14104"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0831"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18311"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18139"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000809"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17705"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.05.021"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15575"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18137"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15346"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.10.023"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14890"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-022-00396-1"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000780"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16549"},{"key":"e_1_2_10_25_1","unstructured":"Domeingroep Allergie en eczeem domeingroep Kinderdermatologie VMCE. Upadacitinib (standpunt). Available from: Standpunten en leidraden (nvdv.nl). Assessed July 2022."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.100102.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3751"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1246"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-021-02185-3"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1513"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1699516"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00558-0"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06305.x"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06270.x"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18558"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.08.450"},{"key":"e_1_2_10_38_1","unstructured":"Bundesanstalt f\u00fcr Arbeitsschutz und Arbeitsmedizin.TRGS 401: Risks Resulting from Skin Contact\u2014Identification Assessment Measures[Internet].2008. Assessed July 2022.https:\/\/www.baua.de\/DE\/Angebote\/Rechtstexte-und-Technische-Regeln\/Regelwerk\/TRGS\/TRGS-401.html"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.shaw.2014.08.001"},{"key":"e_1_2_10_40_1","unstructured":"Global Initiative for Asthma.Global Strategy for Asthma Management and Prevention. Available from: Global Initiative for Asthma (GINA) (ginasthma.org). Assessed July 2022."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01620.x"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.01.014"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11121-007-0070-9"},{"key":"e_1_2_10_45_1","unstructured":"SimpsonEL RahawiK HuX.Effect of Upadacitinib on Hand Eczema in Patients With Moderate\u2010to\u2010Severe Atopic Dermatitis: Results from Two Phase 3 Trials (Measure Up 1 and Measure Up 2). Presented at the 30th European Academy of Dermatology and Venereology Congress September 29\u2013October 2 2021 EADV Virtual Congress (e\u2010poster unpublished)."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0413-2"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2087059"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18469"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21037"},{"key":"e_1_2_10_50_1","unstructured":"Business Wire.Asana biosciences announces positive topline results from phase 2b study of oral JAK\u2010SYK inhibitor gusacitinib (ASN002) in patients with chronic hand eczema: rapid and significant improvement demonstrated [press release]. Available from: Asana BioSciences Announces Positive Topline Results from Phase 2b Study of Oral JAK\/SYK Inhibitor Gusacitinib (ASN002) in Patients with Chronic Hand Eczema: Rapid and Significant Improvement Demonstrated | Business Wire. Assessed July 2022."},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-019-0095-3"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4778"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1151-6"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_10_55_1","unstructured":"Smoking Pack Years. Available from: Home | Smoking Pack Years. Assessed July 2022."},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12912"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12993"}],"container-title":["Contact Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cod.14276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cod.14276","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cod.14276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T23:37:36Z","timestamp":1692661056000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cod.14276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/cod.14276"],"URL":"https:\/\/doi.org\/10.1111\/cod.14276","archive":["Portico"],"relation":{},"ISSN":["0105-1873","1600-0536"],"issn-type":[{"value":"0105-1873","type":"print"},{"value":"1600-0536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"2022-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}